Circassia Initiates Pivotal Phase 3 ToleroMune® Trial In Cat Allergen-Induced Rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, has announced the start of a pivotal phase 3 trial of its investigational ToleroMune(R) cat allergy treatment for cat allergen-induced rhinoconjunctivitis...
Read more »